Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination
K Miyauchi, T Tsuchikawa, M Wada, T Abiko… - …, 2016 - Future Medicine
K Miyauchi, T Tsuchikawa, M Wada, T Abiko, N Kyogoku, T Shichinohe, Y Miyahara…
Immunotherapy, 2016•Future MedicineAim: To investigate the antigen spreading pattern in the CHP-MAGE-A4-vaccinated patients
and analyze the clinical relevance of antigen spreading pattern as a surrogate marker of
patient survival. Materials & methods: 12 patients who had been injected with 300 μg of CHP-
MAGE-A4 and 0.5 Klinische Einheit of OK-432 in more than five vaccinations were analyzed.
Results: Increases in the anti-MAGE-A4-specific antibody response were observed in eight
patients (66.7%), compared with six patients (50%) for anti-NY-ESO-1 and five patients …
and analyze the clinical relevance of antigen spreading pattern as a surrogate marker of
patient survival. Materials & methods: 12 patients who had been injected with 300 μg of CHP-
MAGE-A4 and 0.5 Klinische Einheit of OK-432 in more than five vaccinations were analyzed.
Results: Increases in the anti-MAGE-A4-specific antibody response were observed in eight
patients (66.7%), compared with six patients (50%) for anti-NY-ESO-1 and five patients …
Aim
To investigate the antigen spreading pattern in the CHP-MAGE-A4-vaccinated patients and analyze the clinical relevance of antigen spreading pattern as a surrogate marker of patient survival. Materials & methods
12 patients who had been injected with 300 μg of CHP-MAGE-A4 and 0.5 Klinische Einheit of OK-432 in more than five vaccinations were analyzed. Results
Increases in the anti-MAGE-A4-specific antibody response were observed in eight patients (66.7%), compared with six patients (50%) for anti-NY-ESO-1 and five patients (41.7%) for anti-MAGE-A3 after five vaccinations. We identified frequent antigen spreading following MAGE-A4 vaccinations without associations with the clinical response or patient prognosis. Conclusion
Antigen spreading pattern might reflect tumor shrinkage as a response to treatment and treatment history (clinical trial registration number: UMIN000001999).
Future Medicine